The EAACI Congress 2025 offers an exclusive platform for industry leaders to showcase innovations in allergy and immunology. The exhibition area will feature cutting-edge products and therapies, ...

In the study, treatment with AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6), led to faster radiographic fusion and a higher fusion success rate, as well as greater improvements in ...

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...

Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models HOUSTON, March ...

To participate in the study, please visit www.rawoodfoundation.org/hptumorregistry to enroll into the Hypothalamic-Pituitary Brain Tumors Patient Registry and complete the available surveys. For those ...

Nikhil Lalwani, President and CEO of ANI stated, “This transaction reflects our commitment to strengthening our Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating ...

Prime Medicine’s program leverages the Company’s universal liver lipid nanoparticle (LNP) to edit the E342K (Pi*Z) mutation in the SERPINA1 gene, the prevalent disease-causing mutation in AATD, ...

Net Revenue: Total net revenues for the fourth quarter of 2024 increased 59% to $11.6 million compared to $7.3 million in the prior year period, driven primarily by growth in ALKINDI SPRINKLE and ...

EBX-102-02 is a next-generation full-spectrum microbiome product that contains a high-diversity microbiome consortium, stabilised within a dried, off-white odourless powder. EBX-102-02 is designed to ...

The Tecan Group (SIX Swiss Exchange: TECN) today published the agenda of the Annual General Meeting on April 10, 2025. Karen Huebscher, who has served as a member of the Board of Directors since 2012, ...

The new non-executive employee received an option to purchase 35,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $2.60, which was the ...

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the ...